These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 34233082)
21. New coumarin derivatives: design, synthesis and use as inhibitors of hMAO. He X; Chen YY; Shi JB; Tang WJ; Pan ZX; Dong ZQ; Song BA; Li J; Liu XH Bioorg Med Chem; 2014 Jul; 22(14):3732-8. PubMed ID: 24856304 [TBL] [Abstract][Full Text] [Related]
29. Positional scanning of natural product hispidol's ring-B: discovery of highly selective human monoamine oxidase-B inhibitor analogues downregulating neuroinflammation for management of neurodegenerative diseases. Hassan AHE; Kim HJ; Gee MS; Park JH; Jeon HR; Lee CJ; Choi Y; Moon S; Lee D; Lee JK; Park KD; Lee YS J Enzyme Inhib Med Chem; 2022 Dec; 37(1):768-780. PubMed ID: 35196956 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of 3-arylcoumarins as potential anti-Alzheimer's disease agents. Yang J; Zhang P; Hu Y; Liu T; Sun J; Wang X J Enzyme Inhib Med Chem; 2019 Dec; 34(1):651-656. PubMed ID: 30746966 [TBL] [Abstract][Full Text] [Related]
31. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Matos MJ; Viña D; Quezada E; Picciau C; Delogu G; Orallo F; Santana L; Uriarte E Bioorg Med Chem Lett; 2009 Jun; 19(12):3268-70. PubMed ID: 19423346 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease. Joubert J; Foka GB; Repsold BP; Oliver DW; Kapp E; Malan SF Eur J Med Chem; 2017 Jan; 125():853-864. PubMed ID: 27744252 [TBL] [Abstract][Full Text] [Related]
34. MAO inhibitors and their wider applications: a patent review. Carradori S; Secci D; Petzer JP Expert Opin Ther Pat; 2018 Mar; 28(3):211-226. PubMed ID: 29324067 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. Gnerre C; Catto M; Leonetti F; Weber P; Carrupt PA; Altomare C; Carotti A; Testa B J Med Chem; 2000 Dec; 43(25):4747-58. PubMed ID: 11123983 [TBL] [Abstract][Full Text] [Related]
36. Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. Catto M; Nicolotti O; Leonetti F; Carotti A; Favia AD; Soto-Otero R; Méndez-Alvarez E; Carotti A J Med Chem; 2006 Aug; 49(16):4912-25. PubMed ID: 16884303 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. Matos MJ; Terán C; Pérez-Castillo Y; Uriarte E; Santana L; Viña D J Med Chem; 2011 Oct; 54(20):7127-37. PubMed ID: 21923181 [TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease. Zhang C; Yang K; Yu S; Su J; Yuan S; Han J; Chen Y; Gu J; Zhou T; Bai R; Xie Y Eur J Med Chem; 2019 Oct; 180():367-382. PubMed ID: 31325784 [TBL] [Abstract][Full Text] [Related]
39. Coumarin-Rasagiline Hybrids as Potent and Selective hMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents. Matos MJ; Herrera Ibatá DM; Uriarte E; Viña D ChemMedChem; 2020 Mar; 15(6):532-538. PubMed ID: 32037726 [TBL] [Abstract][Full Text] [Related]
40. Predicting monoamine oxidase inhibitory activity through ligand-based models. Vilar S; Ferino G; Quezada E; Santana L; Friedman C Curr Top Med Chem; 2012; 12(20):2258-74. PubMed ID: 23231398 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]